Loading
Life sciences · Journal article
Pharmaceuticals · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Objectives: The neurotensin subtype-1 receptor (NTS1R) is overexpressed in a number of human tumors, representing a valid biomolecular target for neurotensin-based radionuclide carriers. The latter are designed to deposit diagnostic–therapeutic radionuclides specifically on cancer lesions. This review summarizes research efforts toward the development, preclinical evaluation and first clinical outcomes of neurotensin-based radioligands in the diagnosis and therapy—radiotheranostics—of NTS1R-positive cancer. Methods: The preclinical and few clinical studies related to NTS1R-targeted radiotheranostics are discussed. The crucial issue of in vivo metabolic stability is highlighted. Results: Much effort has been dedicated to the development of effective NTS1R-directed radioligands for cancer theranostics, most of which are peptide-based. However, clinical success has been sub-optimal thus far, partly as a result of their fast degradation in the biological milieu. Conclusions: The administration of key protease inhibitor regimens, the introduction of branched or otherwise stabilized analogs and the advent of non-peptidic NTS1R-antagonists are some of the new promising approaches towards achieving clinical breakthroughs in the battle against NTS1R-expressing cancer.